Aravive S6

Drug Profile

Aravive S6

Alternative Names: Aravive S-6; Ruga-S6

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Stanford University
  • Developer Aravive Biologics
  • Class Proteins
  • Mechanism of Action Axl receptor tyrosine kinase modulators; Growth arrest-specific protein 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Solid tumours
  • Discontinued Viral infections

Most Recent Events

  • 03 Jan 2017 Discontinued - Preclinical for Viral infections in USA (Parenteral) (Aravive Biologics website, January 2017)
  • 06 Dec 2016 Aravive plans a phase I/II trial for Solid tumour in USA
  • 21 Nov 2016 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top